|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recombinant EMC isolates of MERS-CoV, in which the S protein is replaced with those of Amibara isolates, were then generated to test the roles of these proteins in viral properties.
|
31275264 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, changes D510G and I529T increased resistance of S protein-driven entry to neutralization by monoclonal antibodies and sera from MERS patients.
|
30404801 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells.
|
31614169 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The receptor-binding domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for development of MERS vaccines and therapeutics.
|
30646569 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported.
|
31428074 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, this review provides informative guidance for designing and developing safe and effective MERS vaccines based on viral S protein.
|
30058403 |
2018 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: This review illustrates MERS-CoV S protein's structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS-CoV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides.
|
27936982 |
2017 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review briefly describes the structure of the MERS-CoV spike (S) protein and its receptor-binding domain (RBD), discusses the current status of MERS vaccine development and illustrates the strategies used to develop RBD-based subunit vaccines against MERS.
|
25445336 |
2015 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Murine betacoronavirus (β-CoV) in group A uses the N-terminal domain (NTD) of S protein to bind to its receptor, whereas the β-CoVs severe acute respiratory syndrome CoV in group B and Middle East respiratory syndrome CoV in group C and several α-CoVs use the downstream C domain in their S proteins to recognize their receptor proteins.
|
26085157 |
2015 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, the current advancements and potential strategies in the development of MERS vaccines, particularly subunit vaccines based on MERS-CoV spike (S) protein and its receptor-binding domain (RBD), are discussed.
|
24766432 |
2014 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus.
|
24067982 |
2013 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.
|
23824801 |
2013 |